AWA
VVOS icon

Acorn Wealth Advisors’s Vivos Therapeutics VVOS Stock Holding History

Acorn Wealth Advisors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.72K Hold
14,776
– – ﹤0.01% 303
2026
Q1 		$17.4K Hold
14,776
– – 0.01% 263
2025
Q4 		$30K Buy
+14,776
New +$36.6K 0.01% 266

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Acorn Wealth Advisors's VVOS Position: Q2 2026 in Review

Acorn Wealth Advisors held its Vivos Therapeutics (VVOS) position steady in Q2 2026 at 14,776 shares worth $6.72K. The position accounts for ﹤0.01% of the portfolio, ranked #303.

Acorn Wealth Advisors first reported a position in VVOS in Q4 2025 and has held it in 3 quarters since. The position peaked at $30K in Q4 2025. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • Acorn Wealth Advisors held 14,776 shares of Vivos Therapeutics worth $6.72K as of Q2 2026.
  • Acorn Wealth Advisors left its Vivos Therapeutics share count unchanged in Q2 2026.
  • Vivos Therapeutics made up ﹤0.01% of Acorn Wealth Advisors's portfolio in Q2 2026, its #303 holding.
  • Acorn Wealth Advisors first reported a position in Vivos Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Acorn Wealth Advisors's Vivos Therapeutics position peaked at $30K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on Acorn Wealth Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.